Optimizing Dendritic Cell-Based Approaches for Cancer Immunotherapy
Dendritic cells (DC) are professional antigen-presenting cells uniquely suited for cancer immunotherapy. They induce primary immune responses, potentiate the effector functions of previously primed T-lymphocytes, and orchestrate communication between innate and adaptive immunity. The remarkable dive...
Main Authors: | Datta, Jashodeep, Terhune, Julia H., Lowenfeld, Lea, Cintolo, Jessica A., Xu, Shuwen, Roses, Robert E., Czerniecki, Brian J. |
---|---|
Format: | Online |
Language: | English |
Published: |
YJBM
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257036/ |
Similar Items
-
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
by: Datta, Jashodeep, et al.
Published: (2015) -
Novel strategy to identify MHC class II-promiscuous CD4+ peptides from tumor antigens for utilization in vaccination
by: Datta, Jashodeep, et al.
Published: (2014) -
Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy
by: Terhune, Julia, et al.
Published: (2013) -
Calcium ionophore pre-treatment induces type-1 polarized DCs with enhanced T cell stimulatory function and IL-12 production
by: Berk, Erik, et al.
Published: (2013) -
Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer
by: Datta, Jashodeep, et al.
Published: (2015)